-
公开(公告)号:US09957265B2
公开(公告)日:2018-05-01
申请号:US14778052
申请日:2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor: Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kurukulasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
-
公开(公告)号:US10059705B2
公开(公告)日:2018-08-28
申请号:US14778055
申请日:2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor: Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Christopher F. Thompson , Danielle Falcone , Wei Deng , Luis Torres , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng , Mark E. Scott
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
3.ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 审中-公开
Title translation: 交联氰基乙基吡唑啉酮作为甘油激酶抑制剂公开(公告)号:US20160272634A1
公开(公告)日:2016-09-22
申请号:US14778055
申请日:2014-03-19
Applicant: Christopher DINSMORE , Peter FULLER , David GUERIN , Jason David KATZ , Christopher F. THOMPSON , Danielle FALCONE , Wei DENG , Luis TORRES , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , Mark E. SCOTT , MERCK SHARP & DOHME CORP.
Inventor: Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Christopher F. Thompson , Danielle Falcone , Wei Deng , Luis Torres , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng , Mark E. Scott
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Abstract translation: 本发明提供了作为JAK抑制剂的式I化合物,因此可用于治疗JAK介导的疾病如类风湿性关节炎,哮喘,COPD和癌症。
-
4.
公开(公告)号:US20140228348A1
公开(公告)日:2014-08-14
申请号:US14345978
申请日:2012-09-21
Applicant: MERCK SHARP& DOHME CORP.
Inventor: Jason Brubaker , Matthew Lloyd Childers , Matthew Christopher , Joshua T. Close , Jason David Katz , Joon Jung , Scott Peterson , Phieng Siliphaivanh , Tony Siu , Graham Frank Smith , Luis E. Torres , Hyun Chong Woo , Jonathan R. Young , Hongjun Zhang
IPC: C07D231/38 , C07D405/04 , C07D401/14 , C07D401/04 , C07D403/04
CPC classification number: C07D405/08 , C07D231/38 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Abstract translation: 本发明提供了作为JAK抑制剂的式I化合物,因此可用于治疗JAK介导的疾病如类风湿性关节炎,哮喘,COPD和癌症。
-
5.N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
Title translation: N-(2-氰基杂环基)吡唑并吡喃酮作为甘薯激酶抑制剂公开(公告)号:US20160272633A1
公开(公告)日:2016-09-22
申请号:US14778052
申请日:2014-03-19
Applicant: Christopher DINSMORE , Peter FULLER , David GUERIN , Christopher F. THOMPSON , Qinglin PU , Mark E. SCOTT , Jason David KATZ , Ravi KURUKLASURIYA , Joshua T. CLOSE , Danielle FALCONE , Jason BRUDAKER , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , MERCK SHARP & DOHME CORP.
Inventor: Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kuruklasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
-
6.GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
Title translation: 作为JANUS KINASE抑制剂的GEMYALLY取代的氰基乙基吡唑啉吡啶公开(公告)号:US20160272632A1
公开(公告)日:2016-09-22
申请号:US14778046
申请日:2014-03-19
Applicant: Matthew Lloyd CHILDERS , Peter FULLER , David GUERIN , Jason David KATZ , Qinglin PU , Mark E. SCOTT , Christopher E. THOMPSON , Michelle MARTINEZ , Danielle FALCONE , Luis TORRES , Yongqi DENG , Ravi KURUKULASURIYA , Hongbo ZENG , Yunfeng BAI , Norman KONG , Yumei LIU , MERCK SHARP & DOHME CORP.
Inventor: Matthew Lloyd Childers , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Michelle Martinez , Danielle Falcone , Luis Torres , Yongqi Deng , Ravi Kurukulasuriya , Hongbo Zeng , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Abstract translation: 本发明提供了作为JAK抑制剂的式(I)化合物,因此可用于治疗JAK介导的疾病如类风湿性关节炎,哮喘,COPD和癌症。
-
公开(公告)号:US09957264B2
公开(公告)日:2018-05-01
申请号:US14778046
申请日:2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor: Matthew Lloyd Childers , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Michelle Martinez , Danielle Falcone , Luis Torres , Yongqi Deng , Ravi Kurukulasuriya , Hongbo Zeng , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
公开(公告)号:US09725445B2
公开(公告)日:2017-08-08
申请号:US14778019
申请日:2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor: Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
9.CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权
Title translation: 甘氨酸激酶抑制剂CYCLOALKYL NITRILE PYRAZOLO PYRIDONES公开(公告)号:US20160280704A1
公开(公告)日:2016-09-29
申请号:US14778019
申请日:2014-03-19
Applicant: Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng , Merck Sharp & Dohme Corp.
Inventor: Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
-
-
-
-
-
-
-